Skip to content
Screener

AOCI at other companies

Abbott logo
AbbottABT
-$6.21B+5.5%
Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
-$1.76B-2.8%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
-$2.5B-6.6%
Danaher logo
DanaherDHR
-$795M-39.7%
Quanterix Corporation logo
Quanterix CorporationQTRX
-$1.01M+44.4%
QuidelOrtho Corporation logo
QuidelOrtho CorporationQDEL
-$4.1M+82.8%

Other financials

Income statement

See full
Revenue$592.1M+1.1%
Gross profit$309.4M+1.1%
Operating income$34.1M+43.9%
Net income-$527.1M-924%
EPS (diluted)-$19.55-954%

Balance sheet

See full
Cash & equivalents$509.0M-2.7%
Total debt$987.3M-28.4%
Total equity$6.9B+2.6%
Total assets$9.8B+2.8%

Cash flow

See full
Operating cash flow$108.1M-16.8%
CapEx$30.0M-12.8%
Free cash flow$78.1M-18.2%

Valuation

See full
Market cap$9.3B+30.0%
Enterprise value$9.78B+19.3%
P/E55.1×+32.7×
P/S3.6×+0.8×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin8.8%-3.1pp
Net margin6.5%+3.4pp
FCF margin13.8%-0.2pp

Returns & leverage

See full
Return on equity2.5%+1.3pp
Debt / equity0.1×-0.1×
Current ratio3.2×-2.8×

Where this comes from

Reported directly by Bio-Rad Laboratories in its filing.

Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.

The source filing: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:19 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000012208-26-000035
LIABILITIES AND STOCKHOLDERS’ EQUITYMarch 31, 2026 / (Unaudited)December 31, 2025
Class A common stock, $0.0001 par value; 80,000,000 shares authorized; shares issued - 25,199,880 and 25,199,760 as of March 31, 2026 and December 31, 2025, respectively; shares outstanding - 21,762,498 and 21,924,284 as of March 31, 2026 and December 31, 2025, respectively
Class B common stock, $0.0001 par value; 20,000,000 shares authorized; shares issued and outstanding - 5,065,990 as of March 31, 2026 and 5,066,110 as of December 31, 2025, respectively
Additional paid-in capital490.5476.0
Class A treasury stock at cost, 3,437,382 and 3,275,476 shares as of March 31, 2026 and December 31, 2025, respectively(1,053.0)(1,009.6)
Retained earnings7,649.28,176.3
Accumulated other comprehensive income (loss)(235.4)(189.1)
Total stockholders’ equity6,851.37,453.6
Total liabilities and stockholders’ equity$9,790.0$10,576.5

Item 1. Financial Statements (Unaudited)

FAQ

What is Bio-Rad Laboratories's AOCI?
Bio-Rad Laboratories (BIO) reported AOCI of -$235.4M in Q1 2026.
How has Bio-Rad Laboratories's AOCI changed year-over-year?
Bio-Rad Laboratories's AOCI increased by 42.6% year-over-year, from -$409.8M to -$235.4M.
What is the long-term trend for Bio-Rad Laboratories's AOCI?
Over 5 years (2020 to 2025), Bio-Rad Laboratories's AOCI has grown at a -7.7% compound annual growth rate (CAGR), from $282.46M to -$189.1M.
What does AOCI mean?
Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.

Ask your AI about Bio-Rad Laboratories's aoci.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude